A securities class action has been initiated against Picard Medical, Inc. (NYSE: PMI), alleging the company engaged in fraudulent conduct including false statements and coordinated insider share sales during a period of artificial price inflation. According to the complaint filed by Bronstein, Gewirtz & Grossman LLC, the scheme involved the use of social media misinformation to artificially boost the stock price while insiders opportunistically divested their holdings.
Investors who purchased PMI securities between September 2, 2025, and October 31, 2025, may be eligible to participate in the litigation. The class action seeks to recover damages on behalf of shareholders who allegedly suffered losses as a result of the fraudulent conduct. Interested parties have until April 3, 2026, to request appointment as lead plaintiff in the case, after which the litigation will proceed toward discovery and potential resolution.
The case represents one of several recent securities fraud actions involving alleged market manipulation through digital channels and coordinated trading activity by company insiders.